Welcome to our dedicated page for Immutep news (Ticker: IMMP), a resource for investors and traders seeking the latest updates and insights on Immutep stock.
Immutep Limited reports clinical and corporate developments as a clinical-stage biotechnology company developing Lymphocyte Activation Gene-3 (LAG-3) related immunotherapies for cancer and autoimmune diseases. Its updates center on eftilagimod alfa (efti), a LAG-3 immunotherapy evaluated in cancer studies, and IMP761, a LAG-3 agonist antibody for autoimmune disease.
Recurring company news covers trial results and changes across programs such as TACTI-004, INSIGHT-003 and EFTISARC-NEO, FDA orphan drug designation for efti in soft tissue sarcoma, scientific-conference abstracts, development and commercialization collaborations, quarterly activities reports, cash runway commentary and Nasdaq ADR listing compliance matters.
Immutep (NASDAQ: IMMP) reported pooled results from five clinical trials of eftilagimod alfa (efti) plus standard-of-care in 5,922 late-stage cancer patients. Efti 30 mg SC increased absolute lymphocyte count (ALC) versus SOC alone, and ALC responders in the efti+SOC group showed a median overall survival improvement of +7.7 months (p=0.00171) over non-responders.
Efti treatment was also linked to higher TH1 biomarkers and enhanced T-cell function, suggesting broad immune activation associated with improved clinical benefit across multiple tumor types. Separately, Immutep discontinued the TACTI-004 Phase III trial in March 2026 after an interim futility analysis.
Immutep (NASDAQ: IMMP / ASX: IMM) announced discontinuation of the TACTI-004 Phase III 1L NSCLC trial after an IDMC-recommended interim futility analysis, with a root cause review underway through Q3 CY2026. Cash and term deposits total A$110.6 million, providing runway into H1 CY2028; IMP761 Phase I shows favourable safety and moves to MAD, with data due at EULAR June 2026. The Company expects a US$10 million payment obligation to Dr. Reddy’s in June 2026 and is implementing cost reductions while winding down TACTI-004.
Immutep (NASDAQ: IMMP) received a Nasdaq notice that its American Depositary Shares failed to meet the US$1.00 minimum bid price under Nasdaq Listing Rule 5450(a)(1) for the 30 consecutive business days ended April 24, 2026.
Nasdaq has given an initial 180-calendar-day compliance period through October 26, 2026, during which Immutep must achieve a closing ADS bid of at least US$1.00 for ten consecutive business days to regain compliance. Trading and the company’s ASX listing remain unaffected. The company will monitor the ADS price and consider options but stated there is no assurance it will regain compliance.
Immutep (NASDAQ: IMMP) announced an abstract has been accepted for poster presentation at the ASCO 2026 Annual Meeting in Chicago, 29 May–2 June 2026. The poster, titled “Impact of eftilagimod alfa…on lymphocyte activation and survival outcomes in metastatic cancer patients,” is scheduled for 30 May 2026, 1:30 PM–4:30 PM CDT, Poster Board 359, Abstract #2569.
The presentation will report cumulative clinical and translational data across multiple late-stage cancer studies indicating that eftilagimod alfa (efti), an APC activator via MHC class II, induces rapid and sustained lymphocyte activation associated with improved overall survival in metastatic patients.
Immutep (NASDAQ: IMMP) announced the FDA has granted Orphan Drug Designation for eftilagimod alfa (efti) to treat soft tissue sarcoma (STS) on April 15, 2026. The designation may provide regulatory support, tax credits, fee waivers and seven years of market exclusivity if approved.
Immutep cited investigator‑initiated Phase II EFTISARC‑NEO data in 38 evaluable patients showing median tumour hyalinization/fibrosis of 51.5%, above the pre‑specified 35% target and historical ~15% with radiotherapy alone; the study reported immune activation signals and a favourable safety profile without surgery delays.
Immutep (NASDAQ: IMMP) reported successful completion of the single ascending dose (SAD) portion of its first‑in‑human Phase I study of IMP761, a LAG‑3 agonist for autoimmune diseases, with dosing up to 14 mg/kg and no dose‑limiting toxicities observed.
The multiple ascending dose (MAD) portion is ongoing, with MAD completion expected in Q3 2026. According to the company, IMP761 produced a durable immunosuppressive effect in an intradermal antigen challenge after a single administration. Phase I data will be presented at EULAR on 4 June 2026.
Immutep (NASDAQ: IMMP) announced on March 13, 2026 that an Independent Data Monitoring Committee recommended discontinuing the TACTI-004 Phase III study in first-line non-small cell lung cancer after a planned interim futility analysis.
Enrollment will be halted, the study will be wound down with patient follow-up and site close-out, and Immutep says it is reviewing the data and next steps. The company now expects its cash runway to extend well beyond its prior guidance of Q2 CY2027 and will provide an updated outlook after operational assessments.
Immutep (NASDAQ: IMMP) announced it has reached 50% enrolment in the registrational TACTI-004 (KEYNOTE-F91) Phase III trial for first-line advanced/metastatic non-small cell lung cancer. The trial has enrolled 378 patients, with >140 activated clinical sites across 27 countries.
Immutep says the futility analysis remains on track for Q1 CY2026 and patient enrolment completion is expected in Q3 CY2026.
Immutep (NASDAQ: IMMP / ASX: IMM) reported Q2 FY26 operational and clinical progress, highlighted by a strategic collaboration with Dr. Reddy’s for efti outside North America, Europe, Japan and Greater China, with an upfront ~A$30.2M and up to ~A$528.4M in milestones plus royalties.
Key clinical milestones: TACTI-004 Phase III enrolment progressing (289 patients, ~38% of target), EFTISARC-NEO met its primary endpoint, INSIGHT-003 showed strong 1L NSCLC responses, IMP761 Phase I dosing advanced, four patents granted, and pro-forma cash of ~A$129.3M extending runway into Q2 CY2027.
Immutep (NASDAQ: IMMP / ASX: IMM) reported a positive Phase I update for IMP761, a first-in-class LAG-3 agonist antibody for autoimmune diseases.
The single-ascending dose portion completed 2.5 mg/kg and 7 mg/kg cohorts with a favourable safety profile and no treatment-related adverse reactions beyond mild intensity. Dose-dependent immunosuppression was observed with significant, durable inhibition of three T-cell-mediated intradermal reactions at days 2, 9 and 23. The company said a PK/PD relationship was established between 1 and 7 mg/kg.
The trial will continue as planned and additional updates, including a possible presentation at a major medical conference, are anticipated in 1H CY2026.